Tectonic Therapeutic, Inc. TECX
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2018 · data as of November 13, 2026
Tectonic Therapeutic, Inc. (TECX) is a healthcare company listed in the US with a market value of about $422M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -39%.
About Tectonic Therapeutic
Tectonic Therapeutic is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2018. It was profitable in 0 of the last 9 years in our data. Its share count rose by 1372% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — |
| Net income | -$74M | -$58M | -$43M | -$106M | -$119M | -$120M | -$73M | -$46M | -$19M |
| Free cash flow | -$60M | -$59M | -$41M | -$97M | -$100M | -$100M | -$69M | -$39M | -$17M |
| EPS (diluted) | $-4.05 | $-6.83 | $-33.76 | $-85.02 | $-0.10 | $-0.12 | $-0.09 | $-0.13 | $-0.29 |
| Net margin | — | — | — | — | — | — | — | — | — |
| ROIC | -26.3% | -40.5% | — | — | -50.5% | -37.3% | -32.2% | -29.9% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $71.00, 236% above the current price; targets range from $26.00 to $93.00; the consensus rating is “Strong buy”; expected EPS is $-5.77 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Tectonic Therapeutic pay a dividend?
Not currently.
Is Tectonic Therapeutic a good stock to buy?
We do not give buy or sell advice. Tectonic Therapeutic scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.